Product Description
ELU001 is a new chemical entity described as a C'Dot drug conjugate (CDC), consisting of payloads (exatecans) and targeting moieties (folic acid analogs) covalently bound by linkers to the C'Dot particle carrier. ELU001 will be the first drug-conjugate of its kind to be introduced into the clinic, a first in class, and a novel molecular entity. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05001282)
Mechanisms of Action: FR1 Inhibitor
Novel Mechanism: No
Modality: Antibody Drug Conjugate
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Elucida Oncology
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Ovarian Diseases|Fallopian Tube Diseases|Fallopian Tube Cancer|Peritoneal Cancer|Uterine Diseases|Endometrial Cancer|Clear Cell Sarcoma|Carcinosarcoma|Uterine Cancer|Clear Cell Adenocarcinoma|Ovarian Cancer|Serous Cystadenocarcinoma|Endometrioid Carcinoma
Phase 1: Acute Myeloid Leukemia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| FRα | P2 |
Terminated |
Uterine Diseases|Ovarian Diseases|Serous Cystadenocarcinoma|Fallopian Tube Cancer|Ovarian Cancer|Endometrial Cancer|Carcinosarcoma|Clear Cell Adenocarcinoma|Fallopian Tube Diseases|Uterine Cancer|Endometrioid Carcinoma|Clear Cell Sarcoma|Peritoneal Cancer |
2024-06-07 |
|
| Pediatric AML | P1 |
Withdrawn |
Acute Myeloid Leukemia |
2024-06-07 |